Randomized Trial of Ciprofloxacin, Azithromycin, and Cefixime for Uncomplicated Typhoid

Select Content Type
Resources
Authored By
Shalina MedSpace
Authored On
Interests
Cardiology
Dermatology
Emergency Medicine
Endocrinology
ENT
Gastroenterology
Hematology
Immunology Allergy & Inflammation
Infectious Disease & Vaccines
Internal/Family Medicine
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Orthopedic
Pain & Anesthesiology
Pediatric Medicine
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology & Nephrology
Speciality
Cardiology
Dentistry
Dermatology
Emergency Medicine
Endocrinology
ENT
Gastroenterology
Geriatrics
Hematology
Immunology Allergy & Inflammation
Infectious Disease & Vaccines
Internal/Family Medicine
Medical Genetics
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Orthopedic
Pain & Anesthesiology
Pathology
Pediatric Medicine
Pharmacology
Psychiatry
Public Health
Pulmonology
Radiology
Rheumatology
Surgery
Urology & Nephrology
Thumbnail Image
randomized trial_thumbnail
Detail Image
randomized trial_mob
Book Detail
Actions
Download in App
Countries of release
India
Nigeria
UAE
IS_Ebsco
false
Description

A randomized controlled trial conducted in Dhaka Medical College Hospital and outpatient settings across Dhaka, Mymensingh, and Sylhet has provided important insights into the treatment of multi-drug resistant (MDR) typhoid fever. The study, carried out from January to December 2017, evaluated the efficacy of ciprofloxacin, azithromycin, and cefixime in treating uncomplicated typhoid caused by Salmonella enterica serovar Typhi. The findings suggested that a seven-day course of azithromycin may be an effective and well-tolerated option for uncomplicated typhoid fever caused by MDR S. Typhi, offering a potential new standard for treatment in regions with high resistance rates.

Published Date